Hydrocodone Bitartrate/Homatropine Methylbromide Tablets CII
Generic Name and Formulations:
Hydrocodone bitartrate 5mg, homatropine methylbromide 1.5mg; tabs.
Various generic manufacturers
Indications for Hydrocodone Bitartrate/Homatropine Methylbromide Tablets:
≥12yrs: 1 tab every 4–6hrs as needed; max 6 tabs/24hrs.
<6yrs: not recommended. 6–11yrs: ½ tab every 4–6hrs as needed; max 3 tabs/24hrs.
Risks from concomitant benzodiazepines or other CNS depressants (see Interactions). Risk of life-threatening respiratory depression (esp. in children). Abuse potential (monitor). Head injury, other intracranial lesions or pre-existing increase in intracranial pressure. Acute abdomen. Hypothyroidism. Addison's disease. Prostatic hypertrophy. Urethral stricture. Asthma. Narrow-angle glaucoma. Severe hepatic or renal impairment. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased risk of respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, opioids, antihistamines, antipsychotics, anxiolytics, alcohol); avoid. May affect or be affected by MAOIs, TCAs.
Respiratory depression, drowsiness, hypertension, orthostatic hypotension, palpitations, anticholinergic effects, sedation, anxiety, nausea, rash, pruritus.
Formerly known under the brand name Hycodan.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness